Immune-based combination therapy for esophageal cancer

Esophageal cancer (EC) is an aggressive malignancy raising a healthcare concern worldwide. Standard treatment options include surgical resection, chemotherapy, radiation therapy, and targeted molecular therapy. The five-year survival rate for all stages of EC is approximately 20%, ranging from 5% to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huiling, Xu, Yufei, Zuo, Fengli, Liu, Junzhi, Yang, Jiqiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797857/
https://www.ncbi.nlm.nih.gov/pubmed/36591219
http://dx.doi.org/10.3389/fimmu.2022.1020290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797857/
https://www.ncbi.nlm.nih.gov/pubmed/36591219
http://dx.doi.org/10.3389/fimmu.2022.1020290

Ejemplares similares